SG115489A1 - Pharmaceutically active morpholinol - Google Patents

Pharmaceutically active morpholinol

Info

Publication number
SG115489A1
SG115489A1 SG200204411A SG200204411A SG115489A1 SG 115489 A1 SG115489 A1 SG 115489A1 SG 200204411 A SG200204411 A SG 200204411A SG 200204411 A SG200204411 A SG 200204411A SG 115489 A1 SG115489 A1 SG 115489A1
Authority
SG
Singapore
Prior art keywords
pharmaceutically active
morpholinol
active morpholinol
pharmaceutically
active
Prior art date
Application number
SG200204411A
Other languages
English (en)
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partridge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SG115489A1 publication Critical patent/SG115489A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG200204411A 1998-01-21 1999-01-20 Pharmaceutically active morpholinol SG115489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22

Publications (1)

Publication Number Publication Date
SG115489A1 true SG115489A1 (en) 2005-10-28

Family

ID=26312986

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200204411A SG115489A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Country Status (30)

Country Link
US (2) US6274579B1 (fr)
EP (2) EP1829544A1 (fr)
JP (1) JP2002501025A (fr)
KR (1) KR100568063B1 (fr)
CN (2) CN1255389C (fr)
AP (1) AP1229A (fr)
AT (1) ATE365042T1 (fr)
AU (1) AU755536B2 (fr)
BR (1) BR9907203A (fr)
CA (1) CA2318268A1 (fr)
CY (1) CY1106828T1 (fr)
DE (1) DE69936335T2 (fr)
DK (1) DK1047428T3 (fr)
EA (1) EA002410B1 (fr)
EE (1) EE04452B1 (fr)
ES (1) ES2288012T3 (fr)
HR (2) HRP20000494B1 (fr)
HU (1) HUP0100900A3 (fr)
ID (1) ID26334A (fr)
IL (2) IL137346A0 (fr)
IS (1) IS2494B (fr)
NO (2) NO326878B1 (fr)
NZ (3) NZ520349A (fr)
PL (1) PL193622B1 (fr)
PT (1) PT1047428E (fr)
SG (1) SG115489A1 (fr)
SK (1) SK10912000A3 (fr)
TR (1) TR200002126T2 (fr)
WO (1) WO1999037305A1 (fr)
YU (1) YU67102A (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
WO1999038504A1 (fr) 1998-01-29 1999-08-05 Sepracor Inc. Utilisations pharmaceutiques de (-)-bupropion optiquement pur
WO1999038503A1 (fr) 1998-01-29 1999-08-05 Sepracor Inc. Usages pharmacologiques de (+)-bupropion optiquement pur
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
AU7750100A (en) * 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2365428C (fr) * 2000-12-21 2008-10-21 Brasscorp Limited Methode pour produire une source de lumiere ultraviolette ou proche de l'ultraviolet destinee a une inspection ou un essai non destructif
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US7109198B2 (en) 2002-05-17 2006-09-19 Duke University Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
ATE413882T1 (de) * 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
CA2522708C (fr) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions influant sur la perte de poids
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
WO2005044809A1 (fr) * 2003-10-27 2005-05-19 Smithkline Beecham Corporation Procede de resolution cinetique dynamique diastereomere permettant de preparer du (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, leurs sels et leurs solvates
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005110405A1 (fr) * 2004-05-03 2005-11-24 Duke University Compositions influant sur la perte de poids
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
CA2635261A1 (fr) * 2006-01-03 2007-07-12 Algebra, Inc. Composes therapeutiques amine-arylsulfonamide conjugues
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TWI504419B (zh) 2006-11-09 2015-10-21 Orexigen Therapeutics Inc 層狀醫藥調配物
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
WO2009158114A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procédés pour traiter des pathologies des graisses viscérales
EP2419400A1 (fr) 2009-04-15 2012-02-22 Research Triangle Institute Inhibiteurs de la recapture des monoamines
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体(政府支援研究または開発)
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-(2-芳基吗啉-4-基)乙酯作为制备抗抑郁药物的应用
DK2858640T3 (da) 2012-06-06 2020-06-29 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
NZ529316A (en) 2004-05-28
KR100568063B1 (ko) 2006-04-07
DE69936335T2 (de) 2008-02-28
EA002410B1 (ru) 2002-04-25
US20020019396A1 (en) 2002-02-14
IS5568A (is) 2000-07-20
KR20010034285A (ko) 2001-04-25
PT1047428E (pt) 2007-09-07
HUP0100900A3 (en) 2002-08-28
EP1047428B1 (fr) 2007-06-20
EP1047428A1 (fr) 2000-11-02
YU67102A (sh) 2004-12-31
AU2328099A (en) 1999-08-09
BR9907203A (pt) 2000-10-17
CN1255389C (zh) 2006-05-10
EP1047428A4 (fr) 2001-12-19
DK1047428T3 (da) 2007-10-08
NO20003721D0 (no) 2000-07-20
TR200002126T2 (tr) 2000-12-21
CY1106828T1 (el) 2012-05-23
EP1829544A1 (fr) 2007-09-05
NZ520349A (en) 2004-02-27
ES2288012T3 (es) 2007-12-16
HRP20000494B1 (en) 2009-02-28
AU755536B2 (en) 2002-12-12
HRP20000494A2 (en) 2000-12-31
EE04452B1 (et) 2005-04-15
US6391875B2 (en) 2002-05-21
SK10912000A3 (sk) 2001-04-09
EA200000691A1 (ru) 2001-04-23
DE69936335D1 (de) 2007-08-02
HRP20051024A2 (hr) 2006-04-30
IL161942A0 (en) 2005-11-20
WO1999037305A1 (fr) 1999-07-29
AP1229A (en) 2003-12-04
NO20003721L (no) 2000-09-19
NO20083529L (no) 2000-09-19
NZ505809A (en) 2002-09-27
ID26334A (id) 2000-12-14
NO326878B1 (no) 2009-03-09
EE200000438A (et) 2001-12-17
CA2318268A1 (fr) 1999-07-29
IS2494B (is) 2009-02-15
AP2000001869A0 (en) 2000-09-30
PL193622B1 (pl) 2007-02-28
IL137346A0 (en) 2001-07-24
JP2002501025A (ja) 2002-01-15
HUP0100900A2 (hu) 2002-05-29
US6274579B1 (en) 2001-08-14
ATE365042T1 (de) 2007-07-15
CN1528753A (zh) 2004-09-15
CN1294513A (zh) 2001-05-09
CN1203858C (zh) 2005-06-01
PL342012A1 (en) 2001-05-07

Similar Documents

Publication Publication Date Title
SG115489A1 (en) Pharmaceutically active morpholinol
GB9823101D0 (en) Pharmaceutically active compounds
EG24411A (en) Pharmaceutically active compounds
GB9924020D0 (en) Pharmaceutically active compounds
IL146117A0 (en) New pharmaceutically active compounds
GB9823102D0 (en) Pharmaceutically active compounds
ZA977807B (en) New pharmaceutically active compounds.
AU5965399A (en) Pharmaceutically active composition
ZA977809B (en) New pharmaceutically active compounds.
ZA977808B (en) New pharmaceutically active compounds.
GB9801230D0 (en) Pharmaceutically active morpholinol
IL158978A0 (en) Pharmaceutically active morpholinol
AU2002315922A1 (en) Pharmaceutically active morpholinol
ZA9811285B (en) New pharmaceutically active compounds
GB9924041D0 (en) Pharmaceutically active compounds
GB9924028D0 (en) Pharmaceutically active compounds
GB9924063D0 (en) Pharmaceutically active compounds
GB9614386D0 (en) Pharmaceutically active compounds
GB9602173D0 (en) Pharmaceutically active compounds
GB9618487D0 (en) Pharmaceutically active compounds
GB9614385D0 (en) Pharmaceutically active compounds
GB9602667D0 (en) Pharmaceutically active compounds
GB9619122D0 (en) Pharmaceutically active compounds
GB9610892D0 (en) Pharmaceutically active compounds
GB9602668D0 (en) Pharmaceutically active compounds